title: Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.
abstract: Although elevated plasma cholesterol levels represent a well-established and significant risk for developing atherosclerosis, there is a wide spectrum of cholesterol levels in patients with coronary artery disease (CAD). Most secondary prevention studies have generated convincing evidence that cholesterol reduction in patients with high cholesterol levels is associated with improved clinical outcome by reducing risk of further cardiovascular events. However, other risk factors may play a prominent role in the pathogenesis of coronary disease in the majority of patients with near-normal cholesterol values. The Cholesterol and Recurrent Events (CARE) study was designed to address whether the pharmacologic reduction of cholesterol levels with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, pravastatin, would reduce the sum of fatal coronary artery disease (CAD) and nonfatal myocardial infarction (MI) in patients who have survived an MI yet have a total cholesterol value < 240 mg/dl (< 6.2 mmol/liter). The other inclusion criteria for this study were age 21-75 years, low density lipoprotein (LDL) cholesterol levels of 115-174 mg/dl (3.0-4.5 mmol/liter), and fasting serum triglyceride levels < 350 mg/dl (< 4.0 mmol/liter). A total of 4,159 eligible consenting patients without other study exclusions were then randomly assigned to receive either pravastatin 40 mg daily or matching placebo in addition to their individualized conventional therapy. The trial was designed to have a median follow-up of 5 years. Study endpoints will be evaluated with respect to predefined subgroups according to baseline lipid values, age, gender, prior cardiovascular risk factors, and history.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Pfeffer
authors.forename: F M
authors.initials: FM
authors.lastname: Sacks
authors.forename: L A
authors.initials: LA
authors.lastname: Moyé
authors.forename: L
authors.initials: L
authors.lastname: Brown
authors.forename: J L
authors.initials: JL
authors.lastname: Rouleau
authors.forename: L H
authors.initials: LH
authors.lastname: Hartley
authors.forename: J
authors.initials: J
authors.lastname: Rouleau
authors.forename: R
authors.initials: R
authors.lastname: Grimm
authors.forename: F
authors.initials: F
authors.lastname: Sestier
authors.forename: W
authors.initials: W
authors.lastname: Wickemeyer
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002170:Canada; D002784:Cholesterol / Q000097:blood*; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014481:United States
chemical_list: D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol